'Cryo-immuno-therapy' is superior to intralesional Candida antigen monotherapy in the treatment of multiple common warts.
Conclusions: 'Cryo-immuno-therapy' is a new combination therapy for multiple common warts. This combination is easy to apply, safe, of low cost, and higher efficacy in contrast to the traditional intralesional Candida antigen monotherapy. PMID: 32009473 [PubMed - as supplied by publisher]
CONCLUSION: Our study showed that Tim-3 might play an important role in the development of AP through regulating the inflammatory response. PMID: 32224541 [PubMed - in process]
Conclusions.SCIT with house dust mixture of ROXALL Medicina España S.A. seems to have an acceptable tolerability profile, induces blocking IgG and decreases skin reactivity. PMID: 32223886 [PubMed - as supplied by publisher]
Purpose of review To report the available information on the current status and future direction of the use of checkpoint inhibitors as novel immunotherapeutic agents in bladder cancer. Recent findings In the past 3 years, five immunotherapies targeting programmed cell death 1 (Pembrolizumab and Durvalumab) or programmed cell death-ligand 1 (PD-L1) (Atezolizumab, nivolumab and Avelumab) pathways have been approved in second-line setting for patients who progressed during or after cisplatin-based chemotherapy. According to the most recent update, these patients should be PD-L1-positive to be eligible for immunotherapy....
CONCLUSIONS: The survey results suggest that dentists' comfort levels and perceived roles in discussing and administering the HPV vaccine vary. PRACTICAL IMPLICATIONS: There is a need to further define the role of dentists and their team members in the promotion and administration of the HPV vaccine. Resources for dentists and dental team members may be helpful to support professional education and communication about the HPV vaccine. PMID: 32222178 [PubMed - in process]
Radiopharmaceutical developer Navidea Biopharmaceuticals has inked a letter...Read more on AuntMinnie.comRelated Reading: Navidea gets 5-year patent extension for Lymphoseek Navidea raises $7.6M, regains listing compliance Navidea claims victories in legal case with former CEO Navidea signs immunotherapy deal with IMV Navidea highlights rheumatoid arthritis results
There ’s a new cell-based cancer immunotherapy on the block.
Conclusions: MBL play an important role in host defense against HPV infection. PMID: 31469597 [PubMed - as supplied by publisher]
This article discusses HPV infiltration and its subtypes involved in plantar warts; the evaluation of patients with plantar warts; and subsequent treatment options, such as laser, Candida albicans immunotherapy, topical therapy such as phytotherapy, and surgical excision.
ABSTRACT Warts are common epidermal growths caused by human papillomavirus that often cause significant discomfort and embarrassment. Current treatment options include topical therapies, cryotherapy, laser vaporization, and surgical excision. Many of these options are destructive and may result in scarring, while less aggressive approaches can lead to lesion recurrence. Additionally, these local modalities are not practical for patients with a large number of warts. Systemic approaches such as immunotherapy have demonstrated success in treating multiple lesions by combining a targeted approach with upregulation of the host...
Discussion Veruccae plantaris or plantar warts are caused by Human papillomavirus which causes benign epidermal tumors that often have a cauliflower pattern on the foot that may be elevated or flush with the surrounding skin. Lesions may resemble calluses but the normal footprint pattern is disrupted. The lesions often have pinpoint hemorrhages that appear as black dots. In an immunocompetent individual, the lesions usually have spontaneous resolution within 2 years but the infection may spread to create additional lesions. The lesions may also cause pain or discomfort because of their size or location. Plantar warts are ...